[go: up one dir, main page]

NO20051804L - GHRH analoger - Google Patents

GHRH analoger

Info

Publication number
NO20051804L
NO20051804L NO20051804A NO20051804A NO20051804L NO 20051804 L NO20051804 L NO 20051804L NO 20051804 A NO20051804 A NO 20051804A NO 20051804 A NO20051804 A NO 20051804A NO 20051804 L NO20051804 L NO 20051804L
Authority
NO
Norway
Prior art keywords
ghrh
relates
present
analogs
human
Prior art date
Application number
NO20051804A
Other languages
English (en)
Inventor
Pierette Gaudreau
Original Assignee
Ct Hospitaller De Universite D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Hospitaller De Universite D filed Critical Ct Hospitaller De Universite D
Publication of NO20051804L publication Critical patent/NO20051804L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)

Abstract

Foreliggende oppfinnelse angår veksthormon frigivende hormon (GHRH) analoger. Mer bestemt angår oppfirmelsen syntetiske GHRH analoger med 29 aminosyrer eller mer, som viser samtidig en øket resistens overfor proteolyse og en høy bindingsaffinitet til human GHRH reseptor i in vitro studier, sammenlignet med humant nativt GHRN (1 29)NH2. Foreliggende oppfirmelse angår også anvendelsen av disse analogene for spesifikk stimulering av in vivo GH fiigiving så vel som fremstilling av et medikament for behandling av GH-mangel-relaterte tilstander. Foreliggende oppfirmelse fremskaffer også en fremgangsmåte for initiering av GHRH induserte biologiske virkninger i et pattedyr.
NO20051804A 2002-09-18 2005-04-13 GHRH analoger NO20051804L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41134002P 2002-09-18 2002-09-18
PCT/CA2003/001418 WO2004027064A2 (en) 2002-09-18 2003-09-17 Ghrh analogues

Publications (1)

Publication Number Publication Date
NO20051804L true NO20051804L (no) 2005-04-13

Family

ID=32030666

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051804A NO20051804L (no) 2002-09-18 2005-04-13 GHRH analoger

Country Status (13)

Country Link
US (2) US20060128615A1 (no)
EP (1) EP1539959A2 (no)
JP (1) JP2006504694A (no)
KR (1) KR20050071498A (no)
CN (1) CN1688696A (no)
BR (1) BR0314619A (no)
CA (1) CA2496687A1 (no)
MX (1) MXPA05002991A (no)
NO (1) NO20051804L (no)
NZ (1) NZ539218A (no)
RU (1) RU2005111253A (no)
WO (1) WO2004027064A2 (no)
ZA (1) ZA200502221B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2610531T3 (es) 2007-03-28 2017-04-28 President And Fellows Of Harvard College Polipéptidos cosidos
EP2142207A4 (en) * 2007-04-04 2013-01-16 Theratechnologies Inc PHARMACEUTICAL FORMULATIONS OF GHRH MOLECULES
US20090088380A1 (en) * 2007-07-12 2009-04-02 Pierrette Gaudreau Ghrh analogs and therapeutic uses thereof
US20100267636A1 (en) * 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
US20100267635A1 (en) * 2009-04-20 2010-10-21 Theratechonolgies Inc. Use of protease inhibitors and grf molecules in combination therapy
US8980249B2 (en) 2010-06-03 2015-03-17 University Of Miami Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
RU2582678C2 (ru) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
US20130261058A1 (en) * 2010-09-16 2013-10-03 University Of Miami Acceleration of wound healing by growth hormone releasing hormone and its agonists
MX2013012259A (es) 2011-04-21 2013-11-22 Theratechnologies Inc Analogos del factor de liberacion de la hormona de crecimiento (grf) y usos de estos.
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
US9079974B2 (en) 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
MX362492B (es) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos.
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014100809A2 (en) 2012-12-21 2014-06-26 University Of Miami Ghrh agonists for the treatment of ischemic disorders
EP2935317B1 (en) 2012-12-21 2019-03-27 University of Miami Ghrh agonists for islet cell transplantation and function and the treatment of diabetes
WO2015100423A2 (en) * 2013-12-24 2015-07-02 University Of Miami Methods for treating cancer with ghrh agonists
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
CN104558150B (zh) * 2014-11-04 2017-12-15 广东药学院 一类生长激素释放激素类似肽及其在制备治疗不孕不育药物中的应用
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
HUE052802T2 (hu) 2016-04-19 2021-05-28 Griffon Pharmaceuticals Int Sa Pegilezett bioaktív peptidek és alkalmazásaik
CN111407884B (zh) * 2019-06-24 2021-12-07 浙江大学 促生长激素释放激素激动剂ghrh-a在制备抗衰老药物中的用途
CN111533800B (zh) * 2020-03-18 2021-08-31 浙江湖州纳福生物医药有限公司 新型生长激素释放激素类似肽改构和二聚体化制备及其应用

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US652047A (en) * 1899-09-23 1900-06-19 Nelson T Shields Artificial tooth.
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
US4301066A (en) * 1980-05-08 1981-11-17 American Home Products Corp. Preparation of (D-Trp 6)-LH-RH via the heptapeptide H-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2
US4439356A (en) * 1981-03-03 1984-03-27 Syva Company Unsymmetrical fluorescein derivatives
US4517181A (en) * 1982-09-15 1985-05-14 The Salk Institute For Biological Studies Mammalian PGRF
US4595676A (en) * 1983-04-26 1986-06-17 The Salk Institute For Biological Studies Rat hypothalamic GRF
US4529595A (en) * 1983-01-13 1985-07-16 The Salk Institute For Biological Studies GRF Analogs
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
US4518586A (en) * 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US4628043A (en) * 1983-04-26 1986-12-09 The Salk Institute For Biological Studies Hypothalamic GRF agonists
US4610976A (en) * 1983-08-29 1986-09-09 The Salk Institute For Biological Studies Porcine GRF
US4605643A (en) * 1984-03-02 1986-08-12 The Salk Institute For Biological Studies Ovine GRF
US4585756A (en) * 1983-10-12 1986-04-29 The Salk Institute For Biological Studies Bovine GRF
US4626523A (en) * 1983-09-13 1986-12-02 The Salk Institute For Biological Studies GRF analogs II
US4528190A (en) * 1983-10-25 1985-07-09 The Salk Institute For Biological Studies GRF Analogs IV
US4622312A (en) * 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
EP0189673B1 (en) * 1984-12-24 1990-09-26 Sumitomo Pharmaceuticals Company, Limited Stable growth hormone releasing factor preparation
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4689318A (en) * 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US4843064A (en) * 1987-01-13 1989-06-27 The Salk Institute For Biological Studies GRF analogs V
US4784987A (en) * 1987-01-13 1988-11-15 The Salk Institute For Biological Studies GRF analogs VI
US5877277A (en) * 1987-09-24 1999-03-02 Biomeasure, Inc. Octapeptide bombesin analogs
US5756458A (en) * 1989-06-16 1998-05-26 Pharmacia & Upjohn Company Stabilized potent GRF analogs
US5137872A (en) * 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
WO1992018531A1 (en) * 1991-04-09 1992-10-29 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
US5262519A (en) * 1991-05-15 1993-11-16 The Salk Institute For Biological Studies GRF analogs XI
US6916489B2 (en) * 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
US6610329B2 (en) * 1993-04-22 2003-08-26 Emisphere Technologies Inc. Compositions for the delivery of antigens
US20010003001A1 (en) * 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SE9301667D0 (sv) * 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US6297212B1 (en) * 1994-05-31 2001-10-02 Gregory M. Fahy Growth hormone therapy and related methods and pharmaceutical compositions
US5837276A (en) * 1994-09-02 1998-11-17 Delab Apparatus for the delivery of elongate solid drug compositions
CA2158782C (en) * 1994-09-23 2010-01-12 Pierrette Gaudreau Marker for growth hormone-releasing factor receptors
US20020111461A1 (en) * 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
IT1285405B1 (it) * 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
CN1130222C (zh) * 1996-01-11 2003-12-10 法玛西雅厄普约翰美国公司 水性延长释放配剂
AU733212B2 (en) * 1996-03-28 2001-05-10 Board Of Trustees Of The University Of Illinois, The Material and methods for making improved liposome compositions
WO1997044354A2 (en) * 1996-05-24 1997-11-27 Regents Of The University Of Minnesota Synthesis of soluble beta-sheet forming peptides
EP1007080B1 (en) * 1996-08-30 2007-04-18 Peptech Limited Formulation for the sustained release of peptide agonists and analogues of GnRH
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
TW577759B (en) * 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation
UA64751C2 (uk) * 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
ATE356139T1 (de) * 1997-06-25 2007-03-15 Pfizer Dipeptidderivate zur förderung der sekretion von wachstumshormon
JP2001511353A (ja) * 1997-07-24 2001-08-14 バレンティス・インコーポレーテッド Ｇｈｒｈの発現システムおよび使用法
AUPO930697A0 (en) * 1997-09-19 1997-10-09 Walter And Eliza Hall Institute Of Medical Research, The Catalytic antibodies and a method of producing same
GB9723955D0 (en) * 1997-11-14 1998-01-07 Generic Biolog Limited Improvements in or relating to detection of molecules in samples
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
WO1999038501A2 (en) * 1998-02-02 1999-08-05 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
US6512162B2 (en) * 1998-07-10 2003-01-28 Calgene Llc Expression of eukaryotic peptides in plant plastids
US20030167531A1 (en) * 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
US6057422A (en) * 1998-11-25 2000-05-02 The Administrators Of The Tulane Educational Fund Antagonistic analogs of GH-RH inhibiting IGF-I and -II
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
EP1141015B1 (en) * 1999-01-06 2009-07-15 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
US6759393B1 (en) * 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
US6437101B1 (en) * 1999-05-07 2002-08-20 Akzo Nobel N.V. Methods for protein purification using aqueous two-phase extraction
US6268178B1 (en) * 1999-05-25 2001-07-31 Phage Biotechnology Corp. Phage-dependent super-production of biologically active protein and peptides
US7078514B1 (en) * 1999-06-12 2006-07-18 Michael O. Thorner Chicken growth hormone releasing hormone receptor
GB9915200D0 (en) * 1999-06-29 1999-09-01 Janssen Pharmaceutica Nv Neurotrophic factor receptor
EP1064934A1 (en) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
BRPI0012688B8 (pt) * 1999-07-23 2021-05-25 Kangawa Kenji método para produzir um composto tipo peptídeo, vetor compreendendo um dna que codifica o composto tipo peptídeo, células microbianas hospedeiras e células microbianas hospedeiras transformadas
US20040192593A1 (en) * 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
KR20020047096A (ko) * 1999-07-26 2002-06-21 크로커 사무엘 에스 초활성 돼지 성장 호르몬 분비 호르몬 유사체
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
ATE381343T1 (de) * 1999-11-03 2008-01-15 Novo Nordisk As Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
EP1258250B1 (en) * 1999-12-28 2005-09-14 Kaken Pharmaceutical Co., Ltd. Nerve protective drugs
US6866851B1 (en) * 1999-12-28 2005-03-15 Washington University GFRα1-RET specific agonists and methods therefor
US20010020012A1 (en) * 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
EP1278858A2 (en) * 2000-03-24 2003-01-29 Millennium Pharmaceuticals, Inc. 46743 and 27417, novel human acyltransferase family members and uses therefor
US7834141B1 (en) * 2000-03-31 2010-11-16 Theresa Siler-Khodr Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy
CA2405709A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
CA2380423A1 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
WO2001092292A2 (en) * 2000-05-30 2001-12-06 Merck & Co., Inc. Ghrelin analogs
JP2004509079A (ja) * 2000-08-02 2004-03-25 セラテクノロジーズ・インコーポレーテッド 効力が増大した修飾生体ペプチド
CA2422707A1 (en) * 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
US6750194B1 (en) * 2000-10-23 2004-06-15 The Procter & Gamble Company Methods of identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors
US20030083299A1 (en) * 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
AU2002246619A1 (en) * 2000-12-08 2003-06-23 Neuronz Limited Use of insuline-like growth factor-i for promoting remyelination of axons
US20030074679A1 (en) * 2000-12-12 2003-04-17 Schwartz Robert J. Administration of nucleic acid sequence to female animal to enhance growth in offspring
US20020091090A1 (en) * 2000-12-28 2002-07-11 Cole Bridget M. Somatostatin antagonists and agonists
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
CN1491233A (zh) * 2001-02-02 2004-04-21 康久化学公司 长效生长激素释放因子衍生物
FR2821359B1 (fr) * 2001-02-27 2003-05-09 Sod Conseils Rech Applic L'heterocarpine, une proteine fixant le ghrh humain
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
CA2446857A1 (en) * 2001-05-10 2002-11-14 Queensland University Of Technology Reproductive cancer diagnosis and therapy
US20030013637A1 (en) * 2001-05-18 2003-01-16 Hideto Ikushima Novel anti-autoimmune composition by inhibition of GRF action
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
PT1397155E (pt) * 2001-06-21 2015-12-07 Genentech Inc Formulação de libertação sustentada
EP1578901A4 (en) * 2001-09-07 2006-03-29 Baylor College Medicine LINEAR DNA FRAGMENTS FOR GENE EXPRESSION
BR0213965A (pt) * 2001-10-26 2005-03-15 Baylor College Medicine Composição e método para alterar as propriedades de massa corporal magra e ósseas em um indivìduo
PL195917B1 (pl) * 2001-10-31 2007-11-30 Inst Farmaceutyczny Nowe peptydy - analogi ludzkiego hormonu uwalniającego hormon wzrostu
JP4602668B2 (ja) * 2001-11-13 2010-12-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するためのフェノキシアミン化合物および組成物
US20050014675A1 (en) * 2001-12-07 2005-01-20 Masahiro Amakawa Cell migration inhibitor
EP1499731B1 (en) * 2002-02-07 2011-05-25 Baylor College Of Medicine Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
WO2003070751A2 (en) * 2002-02-20 2003-08-28 Regents Of The University Of Minnesota Partial peptide mimetics and methods
KR20040091100A (ko) * 2002-03-04 2004-10-27 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 운반체 펩타이드를 함유하는 서방형 의약 조성물
WO2003084983A1 (fr) * 2002-04-11 2003-10-16 Daiichi Suntory Pharma Co., Ltd. Procede de production d'un peptide modifie
WO2003086272A2 (en) * 2002-04-16 2003-10-23 Kamada Ltd. Ultrapure transferrin for pharmaceutical compositions
ES2615484T3 (es) * 2002-05-21 2017-06-07 Daiichi Sankyo Company, Limited Composiciones medicinales que contienen grelina
ES2343061T3 (es) * 2002-05-24 2010-07-22 Medtronic, Inc. Metodos y constructos de dna para produccion de polipeptidos con rendimiento alto.
US20040014645A1 (en) * 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
WO2004001023A2 (de) * 2002-06-20 2003-12-31 Bionethos Holding Gmbh Verfahren und vorrichtung zur vermehrung und differenzierung von zellen in anwesenheit von wachstumsfaktoren und einer biologischen matrix oder trägerstruktur
ATE505476T1 (de) * 2002-07-16 2011-04-15 VGX Pharmaceuticals LLC Codon-optimierte synthetische plasmide
JP2006504653A (ja) * 2002-07-19 2006-02-09 サイトス バイオテクノロジー アーゲー グレリン−担体複合体
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
EP1407779A1 (en) * 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
WO2004105789A1 (en) * 2003-05-29 2004-12-09 Theratechnologies Inc. Grf analog compositions and their use
JP2007515375A (ja) * 2003-07-29 2007-06-14 アレス トレーディング ソシエテ アノニム 多系統萎縮症におけるヒト成長ホルモンの使用
US20050063937A1 (en) * 2003-09-16 2005-03-24 Cheng Li Multiple-arm peptide compounds, methods of manufacture and use in therapy

Also Published As

Publication number Publication date
MXPA05002991A (es) 2005-10-05
ZA200502221B (en) 2006-08-30
KR20050071498A (ko) 2005-07-07
WO2004027064A2 (en) 2004-04-01
BR0314619A (pt) 2005-08-02
NZ539218A (en) 2008-03-28
CA2496687A1 (en) 2004-04-01
EP1539959A2 (en) 2005-06-15
AU2003269631A1 (en) 2004-04-08
US20060128615A1 (en) 2006-06-15
WO2004027064A3 (en) 2004-11-18
CN1688696A (zh) 2005-10-26
JP2006504694A (ja) 2006-02-09
RU2005111253A (ru) 2005-11-20
US20090023646A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
NO20051804L (no) GHRH analoger
ES2212485T3 (es) Compuestos peptidicos analogos del glucagon como peptido-1 (7-37),su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
HUP0004560A2 (hu) Törést gyógyító PTHrP analógok
PT1171465E (pt) Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
RS54215B1 (en) COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
IL210669A0 (en) Glucagon - like - peptide - 2 (glp-2) analogues and pharmaceutical composiitons containing them
CZ20021026A3 (cs) Analogy parathormonu pro léčbu osteoporózy
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
CZ298937B6 (cs) Peptid, který je variantou cásti parathyroidního hormonu a peptidy proteinu, príbuzného parathyroidnímu hormonu
EP1792915A3 (en) Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
DE60140426D1 (de) Pharmazeutische zusammensetzung für muskelanabolismus
JPS63313800A (ja) 副甲状腺ホルモン拮抗剤
WO1996040193A1 (en) CYCLIC ANALOGS OF PTH AND PTHrP
ATE156492T1 (de) Bombesinanaloge
JP2007534613A (ja) レラキシンスーパーファミリーペプチド類似体
KR20200014287A (ko) 장기-작용성 gip 펩타이드 유사체
CN102405229A (zh) 作为甲状旁腺激素(pth)受体激动剂的短链肽
HK1080363A1 (en) Use of compounds having the biological activity ofvasoactive intestinal peptide for the treatment o f sarcoidosis
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
DE60334986D1 (de) Muteine des placental growth factor type 1, herstellungsmethode und anwendung davon
ES2313211T3 (es) Analogos de somatostatina.
Karpf et al. Features of the renal parathyroid hormone‐parathyroid hormone‐related protein receptor derived from structural studies of receptor fragments
CA2730270A1 (en) Dicarba-analogues of octreotide
ATE538806T1 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application